Highlights JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-03 EDT			5-day change	1st Jan Change
29,600 ^KRW	-0.17%		+2.25%	-16.74%

05-27	Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using Ai in Anticancer and Regenerative Medicine	CI
05-14	JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using Ai in Anticancer and Regenerative Medicine	05-27	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	01-22	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates	23-10-20	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Celleron Therapeutics Ltd acquired Argonaut Therapeutics Limited from JW Pharmaceutical Corporation and Oxford Science Enterprises.	23-01-04	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Market Chatter: JW Pharmaceutical Gets German Health Body's Permit for Phase 2a Study of Oral Atopic Dermatitis Drug	21-04-21	MT
Market Chatter: South Korean Drugmakers Queue Up for Clearance of COVID-19 Treatments in January	21-01-04	MT
JW Pharmaceutical Corporation completed the acquisition of 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd.	19-12-30	CI
JW Pharmaceutical Corporation agreed to acquire the remaining 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd..	19-11-26	CI
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China	19-09-27	CI
JW Pharmaceutical Corporation acquired Euvipharm Pharmaceutical Joint-Stock Company.	19-09-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JW Pharmaceutical Corporation

Equities

A001060

KR7001060003

Highlights

Filters